Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial
Question What is the efficacy of concomitant or sequential nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD) as first-line treatment for early-stage unfavorable classic Hodgkin lymphoma? Findings In this investigator-sponsored phase 2 randomized clinical trial including 109 adult patie...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 30, 2020
|
| In: |
JAMA oncology
Year: 2020, Jahrgang: 6, Heft: 6, Pages: 872-880 |
| ISSN: | 2374-2445 |
| DOI: | 10.1001/jamaoncol.2020.0750 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamaoncol.2020.0750
|
| Verfasserangaben: | Paul J. Broeckelmann, Helen Goergen, Ulrich Keller, Julia Meissner, Rainer Ordemann, Teresa V. Halbsguth, Stephanie Sasse, Martin Soekler, Andrea Kerkhoff, Stephan Mathas, Andreas Huettmann, Matthias Bormann, Andreas Zimmermann, Jasmin Mettler, Michael Fuchs, Bastian von Tresckow, Christian Baues, Andreas Rosenwald, Wolfram Klapper, Carsten Kobe, Peter Borchmann, Andreas Engert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1755152450 | ||
| 003 | DE-627 | ||
| 005 | 20230427061321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210416s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2020.0750 |2 doi | |
| 035 | |a (DE-627)1755152450 | ||
| 035 | |a (DE-599)KXP1755152450 | ||
| 035 | |a (OCoLC)1341404778 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bröckelmann, Paul Jan |d 1987- |e VerfasserIn |0 (DE-588)1103596209 |0 (DE-627)861402138 |0 (DE-576)470697962 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma |b the randomized phase 2 German Hodgkin Study Group NIVAHL trial |c Paul J. Broeckelmann, Helen Goergen, Ulrich Keller, Julia Meissner, Rainer Ordemann, Teresa V. Halbsguth, Stephanie Sasse, Martin Soekler, Andrea Kerkhoff, Stephan Mathas, Andreas Huettmann, Matthias Bormann, Andreas Zimmermann, Jasmin Mettler, Michael Fuchs, Bastian von Tresckow, Christian Baues, Andreas Rosenwald, Wolfram Klapper, Carsten Kobe, Peter Borchmann, Andreas Engert |
| 264 | 1 | |c April 30, 2020 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.04.2021 | ||
| 520 | |a Question What is the efficacy of concomitant or sequential nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD) as first-line treatment for early-stage unfavorable classic Hodgkin lymphoma? Findings In this investigator-sponsored phase 2 randomized clinical trial including 109 adult patients, very high interim complete remission rates were observed after treatment with 2 cycles of N-AVD (87%) or 4 doses of nivolumab (51%). After end of treatment with 4 cycles of N-AVD and 30-Gy involved-site radiotherapy, efficacy measures, such as complete remission rates, 1-year progression-free survival, and 1-year overall survival were excellent in both groups. Meaning Nivolumab-based first-line treatment is highly effective in patients with early-stage unfavorable classic Hodgkin lymphoma and warrants further investigation. This phase 2 randomized clinical trial assesses the efficacy of concomitant and sequential treatment with nivolumab and doxorubicin, vinblastine, and dacarbazine (AVD) for patients with early-stage unfavorable Hodgkin lymphoma. IMPORTANCE In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but has not been adequately studied in first-line treatment of early-stage cHL. The NIVAHL trial evaluated nivolumab in this setting with the aim to develop a highly effective yet tolerable systemic therapy to ultimately mitigate morbidity in patients who survive cHL. OBJECTIVE To evaluate efficacy of 2 experimental nivolumab-based first-line treatment strategies in patients with early-stage unfavorable cHL. DESIGN, SETTING, AND PARTICIPANTS This was an open-label, multicenter, phase 2 randomized clinical trial, open between April 2017 and October 2018. The trial took place at 35 trial centers across Germany, ranging from academic centers to private offices. Eligibility was defined by age 18 to 60 years, cHL confirmed by expert pathology review, early-stage unfavorable disease by German Hodgkin Study Group criteria (stage I to II with risk factor[s]), and absence of serious concomitant disease or organ dysfunction. Among 110 enrolled patients, 109 were eligible. INTERVENTIONS Systemic therapy, per random assignment (1:1) to either concomitant treatment with 4 cycles of nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD) or sequential treatment with 4 doses of nivolumab, 2 cycles of N-AVD, and 2 cycles of AVD at standard doses, followed by 30-Gy involved-site radiotherapy. Main Outcomes and Measures Complete remission (CR) rate after study treatment, aiming at excluding a CR rate of 80% or lower via a 2-sided 95% CI for each treatment group. RESULTS Of 109 patients included in this study, 65 (59.6%) were women, and the median (range) age was 27 (18-60) years. At interim staging after 2 cycles of N-AVD or 4 doses of nivolumab monotherapy, 54 of 54 (100%) and 49 of 51 (96%) response-eligible patients, respectively, achieved an objective response, with CR in 47 (87%) and 26 (51%) patients, respectively. Among 101 patients eligible for primary end point analysis, 46 of 51 (90%; 95% CI, 79%-97%) patients receiving concomitant therapy and 47 of 50 (94%; 95% CI, 84%-99%) patients receiving sequential therapy achieved CR after study treatment. With a median follow-up of 13 months, 12-month progression-free survival was 100% for patients receiving concomitant treatment and 98% (95% CI, 95%-100%) for patients receiving sequential therapy. CONCLUSIONS AND RELEVANCE Both strategies combining nivolumab and AVD are feasible and resulted in high remission rates. Despite narrowly missing the efficacy benchmark in the concomitant group, the excellent 12-month progression-free survival and the unexpectedly high CR rate after 4 doses of nivolumab monotherapy warrant further evaluation of this approach in the first-line treatment of patients with early-stage cHL. | ||
| 650 | 4 | |a brentuximab vedotin | |
| 650 | 4 | |a cell transplantation | |
| 650 | 4 | |a failure | |
| 650 | 4 | |a follow-up | |
| 650 | 4 | |a multicohort | |
| 650 | 4 | |a pd-l1 | |
| 650 | 4 | |a response criteria | |
| 650 | 4 | |a risk | |
| 650 | 4 | |a survivors | |
| 700 | 1 | |a Goergen, Helen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Keller, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 700 | 1 | |a Ordemann, Rainer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Halbsguth, Teresa V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sasse, Stephanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soekler, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kerkhoff, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mathas, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huettmann, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bormann, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zimmermann, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mettler, Jasmin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Tresckow, Bastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baues, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kobe, Carsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borchmann, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engert, Andreas |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d Chicago, Ill. : American Medical Association, 2015 |g 6(2020), 6, Seite 872-880 |h Online-Ressource |w (DE-627)818494301 |w (DE-600)2810928-4 |w (DE-576)426501284 |x 2374-2445 |7 nnas |a Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma the randomized phase 2 German Hodgkin Study Group NIVAHL trial |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:6 |g pages:872-880 |g extent:9 |a Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma the randomized phase 2 German Hodgkin Study Group NIVAHL trial |
| 856 | 4 | 0 | |u https://doi.org/10.1001/jamaoncol.2020.0750 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210416 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1755152450 |e 3910874916 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1755152450","title":[{"subtitle":"the randomized phase 2 German Hodgkin Study Group NIVAHL trial","title":"Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma","title_sort":"Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma"}],"id":{"doi":["10.1001/jamaoncol.2020.0750"],"eki":["1755152450"]},"note":["Gesehen am 16.04.2021"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"April 30, 2020","dateIssuedKey":"2020"}],"language":["eng"],"name":{"displayForm":["Paul J. Broeckelmann, Helen Goergen, Ulrich Keller, Julia Meissner, Rainer Ordemann, Teresa V. Halbsguth, Stephanie Sasse, Martin Soekler, Andrea Kerkhoff, Stephan Mathas, Andreas Huettmann, Matthias Bormann, Andreas Zimmermann, Jasmin Mettler, Michael Fuchs, Bastian von Tresckow, Christian Baues, Andreas Rosenwald, Wolfram Klapper, Carsten Kobe, Peter Borchmann, Andreas Engert"]},"person":[{"family":"Bröckelmann","roleDisplay":"VerfasserIn","given":"Paul Jan","display":"Bröckelmann, Paul Jan","role":"aut"},{"given":"Helen","role":"aut","display":"Goergen, Helen","family":"Goergen","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Keller, Ulrich","given":"Ulrich","family":"Keller","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Meißner, Julia","given":"Julia","roleDisplay":"VerfasserIn","family":"Meißner"},{"roleDisplay":"VerfasserIn","family":"Ordemann","display":"Ordemann, Rainer","role":"aut","given":"Rainer"},{"display":"Halbsguth, Teresa V.","role":"aut","given":"Teresa V.","roleDisplay":"VerfasserIn","family":"Halbsguth"},{"family":"Sasse","roleDisplay":"VerfasserIn","given":"Stephanie","role":"aut","display":"Sasse, Stephanie"},{"roleDisplay":"VerfasserIn","family":"Soekler","given":"Martin","display":"Soekler, Martin","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Kerkhoff","display":"Kerkhoff, Andrea","role":"aut","given":"Andrea"},{"family":"Mathas","roleDisplay":"VerfasserIn","display":"Mathas, Stephan","role":"aut","given":"Stephan"},{"given":"Andreas","display":"Huettmann, Andreas","role":"aut","family":"Huettmann","roleDisplay":"VerfasserIn"},{"family":"Bormann","roleDisplay":"VerfasserIn","role":"aut","display":"Bormann, Matthias","given":"Matthias"},{"roleDisplay":"VerfasserIn","family":"Zimmermann","display":"Zimmermann, Andreas","role":"aut","given":"Andreas"},{"display":"Mettler, Jasmin","role":"aut","given":"Jasmin","roleDisplay":"VerfasserIn","family":"Mettler"},{"roleDisplay":"VerfasserIn","family":"Fuchs","given":"Michael","display":"Fuchs, Michael","role":"aut"},{"given":"Bastian","role":"aut","display":"von Tresckow, Bastian","roleDisplay":"VerfasserIn","family":"von Tresckow"},{"family":"Baues","roleDisplay":"VerfasserIn","display":"Baues, Christian","role":"aut","given":"Christian"},{"roleDisplay":"VerfasserIn","family":"Rosenwald","display":"Rosenwald, Andreas","role":"aut","given":"Andreas"},{"display":"Klapper, Wolfram","role":"aut","given":"Wolfram","roleDisplay":"VerfasserIn","family":"Klapper"},{"family":"Kobe","roleDisplay":"VerfasserIn","role":"aut","display":"Kobe, Carsten","given":"Carsten"},{"given":"Peter","display":"Borchmann, Peter","role":"aut","roleDisplay":"VerfasserIn","family":"Borchmann"},{"family":"Engert","roleDisplay":"VerfasserIn","role":"aut","display":"Engert, Andreas","given":"Andreas"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"recId":"818494301","corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Medical Association","role":"isb"}],"pubHistory":["1.2015 -"],"note":["Gesehen am 12.10.2017"],"disp":"Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma the randomized phase 2 German Hodgkin Study Group NIVAHL trialJAMA oncology","title":[{"title":"JAMA oncology","title_sort":"JAMA oncology"}],"id":{"issn":["2374-2445"],"zdb":["2810928-4"],"eki":["818494301"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2015","publisherPlace":"Chicago, Ill.","dateIssuedDisp":"2015-","publisher":"American Medical Association"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2020","extent":"9","pages":"872-880","text":"6(2020), 6, Seite 872-880","issue":"6","volume":"6"}}]} | ||
| SRT | |a BROECKELMAEFFICACYOF3020 | ||